Giant cell arteritis (GCA) is the most common systemic vasculitis in Western countries, with an annual incidence of 10 to 20 per 100,000 adults older than 50 years and increasing with age [1]. Its prognosis can be severe, particularly because of ophthalmic involvement, with permanent visual loss occurring in up to 14% of patients [2], as well as risk of aortitis [3] or stroke [4]. Several clinical patterns of GCA have been described, with cranial and large-vessel GCA the most frequently encountered [5].
